Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2007 2
2009 3
2010 1
2011 1
2012 2
2013 3
2014 4
2015 4
2016 4
2017 1
2018 2
2019 3
2020 4
2021 5
2022 7
2023 6
2024 2
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodríguez-Otero P, Avivi I, Quijano Cardé NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, Mateos MV; RedirecTT-1 Investigators and Study Group. Cohen YC, et al. Among authors: morillo d. N Engl J Med. 2025 Jan 9;392(2):138-149. doi: 10.1056/NEJMoa2406536. N Engl J Med. 2025. PMID: 39778168 Clinical Trial.
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.
Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Vishwamitra D, Skerget S, Verona R, Ma X, Qin X, Ludlage H, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Goldberg JD, Kane C, Heuck C, San-Miguel J, Moreau P. Chari A, et al. Among authors: morillo d. Lancet Haematol. 2025 Apr;12(4):e269-e281. doi: 10.1016/S2352-3026(24)00385-5. Epub 2025 Mar 13. Lancet Haematol. 2025. PMID: 40090350 Free article. Clinical Trial.
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.
Chari A, van de Donk NWCJ, Dholaria B, Weisel KC, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosiñol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi KK, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit D, Wäsch R. Chari A, et al. Among authors: morillo d. Blood. 2025 Sep 22:blood.2025029360. doi: 10.1182/blood.2025029360. Online ahead of print. Blood. 2025. PMID: 40983036
Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.
Gutierrez A, Zeberio I, Peñalver FJ, Martinez-Barranco P, Perez S, Morillo D, Martin X, Nicolas C, Ferrero A, Jimenez-Ubieto A, Bastos-Oreiro M, Davila-Valls J, Calle MV, Perez M, Rodriguez G, Alonso A, Garcia-Noblejas A, Sanchez Argüello D, Knight T, Fernandez Á, Lopez J, Perez De Oteyza J, González de Villambrosia S, Perez E, Marin A, Navarro MB, Fernandez R, Gomez P, Hueso JA, Peñarrubia Ponce MJ, Bravo P, Garcia-Belmonte D, De La Nuez H, Nistal S, Abrisqueta P, Ibañez F, Palomera L, Donato E, Provencio A, Infante MS, Gonzalez-Barca E. Gutierrez A, et al. Among authors: morillo d. Blood Adv. 2025 Oct 14;9(19):4924-4935. doi: 10.1182/bloodadvances.2025016661. Blood Adv. 2025. PMID: 40668613 Free PMC article.
Advanced Glycation End Products: New Clinical and Molecular Perspectives.
Salazar J, Navarro C, Ortega Á, Nava M, Morillo D, Torres W, Hernández M, Cabrera M, Angarita L, Ortiz R, Chacín M, D'Marco L, Bermúdez V. Salazar J, et al. Among authors: morillo d. Int J Environ Res Public Health. 2021 Jul 6;18(14):7236. doi: 10.3390/ijerph18147236. Int J Environ Res Public Health. 2021. PMID: 34299683 Free PMC article. Review.
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS.
Searle E, Cluzeau T, O'Nions J, Recher C, Gyan E, Morillo D, Esteve J, Kulasekararaj A, Raffoux E, Walter HS, Pigneux A, Valcárcel D, Daskalakis N, Bussolari J, Pietsch EC, Kuduk S, Bush T, Zhang X, Philippar U, Oluwasanjo A, Bradford K, Miller J, Van Bogaert C, Curtis M, Chang SY, Guttke C, Gaj S, Pearson R, Murphy J, van Dijck W, Alfonso Piérola A. Searle E, et al. Among authors: morillo d. Br J Haematol. 2025 Jul 1;207(2):624-30. doi: 10.1111/bjh.20224. Online ahead of print. Br J Haematol. 2025. PMID: 40598790 Free PMC article. No abstract available.
Frailty assessment to individualize treatment in older patients with lymphoma.
Hormigo-Sanchez AI, Lopez-Garcia A, Mahillo-Fernandez I, Askari E, Morillo D, Perez-Saez MA, Riesco M, Urrutia C, Martinez-Peromingo FJ, Cordoba R, Gonzalez-Montalvo JI. Hormigo-Sanchez AI, et al. Among authors: morillo d. Eur Geriatr Med. 2023 Dec;14(6):1393-1402. doi: 10.1007/s41999-023-00870-2. Epub 2023 Oct 12. Eur Geriatr Med. 2023. PMID: 37823983 Free PMC article.
59 results